ADAP Adaptimmune Therapeutics plc

+0.06  (+2%)
Previous Close 3.46
Open 3.57
Price To Book 1.68
Market Cap 368,636,280
Shares 104,726,216
Volume 40,853
Short Ratio
Av. Daily Volume 319,177

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 update due 2H 2019.
Soild tumors
Phase 1 update due 1H 2020.
Hepatocellular carcinoma
Phase 1 data May 6, 2019 noted 4/7 stable disease. No partial responses. Update due 2H 2019.
MAGE-A10 (ADP-A2M10)
Non-Small Cell Lung Cancer (NSCLC)
Phase 2 trial to be initiated later in 2019 with interim futility due 1H 2020.
Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS)
Phase 1 trial to be initiated in 2019 with data due in 2020.
Soild tumors

Latest News

  1. Those Who Purchased Adaptimmune Therapeutics (NASDAQ:ADAP) Shares A Year Ago Have A 72% Loss To Show For It
  2. AdaptImmune partners to advance promising cancer immunotherapies
  3. Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
  4. Adaptimmune Reports First Quarter 2019 Financial Results
  5. Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
  6. Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting
  7. Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019
  8. Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting
  9. These 3 Falling Knives Are Expected to Outperform
  10. Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting
  11. Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting
  12. Does Adaptimmune Therapeutics plc (NASDAQ:ADAP) Have A Particularly Volatile Share Price?
  13. Edited Transcript of ADAP earnings conference call or presentation 27-Feb-19 1:00pm GMT
  14. Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
  15. Should You Worry About Adaptimmune Therapeutics plc’s (NASDAQ:ADAP) CEO Salary Level?
  16. Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019
  17. Adaptimmune Therapeutics PLC (ADAP) Upgraded to Buy: Here's What You Should Know
  18. Radius Exceeds 2018 Financial Guidance, Provides Updates
  19. Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4
  20. Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews